YMAB
Closed
Y Mabs Therapeutics
13.82
-0.17 (-1.22%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 13.99
Day's Range: 13.265 - 14.42
Send
sign up or login to leave a comment!
When Written:
6.13
Y-mAbs Therapeutics is a biopharmaceutical company that develops and commercializes antibody-based therapies for the treatment of cancer. The company was founded in 2015 and is headquartered in New York City, with additional offices in Denmark and Switzerland.
Y-mAbs focuses on developing monoclonal antibodies that target specific cancer cells and have the potential to improve patient outcomes. The company's lead product candidate, Danyelza (naxitamab-gqgk), is a monoclonal antibody that targets GD2, a protein found on the surface of certain cancer cells. Danyelza is approved by the U.S. Food and Drug Administration (FDA) for the treatment of high-risk neuroblastoma in pediatric patients.
Y-mAbs is also developing several other antibody-based therapies for the treatment of various types of cancer, including glioblastoma, ovarian cancer, and multiple myeloma. The company's pipeline includes several product candidates in various stages of clinical development.
Y-mAbs has partnerships with several leading academic institutions and biopharmaceutical companies, including Memorial Sloan Kettering Cancer Center, Merck KGaA, and Boehringer Ingelheim. The company is committed to advancing the field of cancer immunotherapy and improving outcomes for patients with cancer.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Y-mAbs focuses on developing monoclonal antibodies that target specific cancer cells and have the potential to improve patient outcomes. The company's lead product candidate, Danyelza (naxitamab-gqgk), is a monoclonal antibody that targets GD2, a protein found on the surface of certain cancer cells. Danyelza is approved by the U.S. Food and Drug Administration (FDA) for the treatment of high-risk neuroblastoma in pediatric patients.
Y-mAbs is also developing several other antibody-based therapies for the treatment of various types of cancer, including glioblastoma, ovarian cancer, and multiple myeloma. The company's pipeline includes several product candidates in various stages of clinical development.
Y-mAbs has partnerships with several leading academic institutions and biopharmaceutical companies, including Memorial Sloan Kettering Cancer Center, Merck KGaA, and Boehringer Ingelheim. The company is committed to advancing the field of cancer immunotherapy and improving outcomes for patients with cancer.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
6.13
Y-mAbs Therapeutics is a biopharmaceutical company that focuses on developing and commercializing innovative antibody-based therapies for the treatment of cancer. The company was founded in 2015 and is headquartered in New York City, with additional offices in Denmark and Switzerland.
Y-mAbs Therapeutics' pipeline includes several clinical-stage products that target various types of cancer, including neuroblastoma, pediatric brain tumors, and lymphoma. The company's lead product candidate, Danyelza (naxitamab-gqgk), is a monoclonal antibody that has been approved by the FDA for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
Y-mAbs Therapeutics uses a proprietary antibody platform technology called omburtamab, which enables the development of highly targeted and specific antibody-based therapies. The company also has collaborations with leading academic institutions and pharmaceutical companies to advance its research and development efforts.
Y-mAbs Therapeutics is committed to improving the lives of patients with cancer by developing innovative and effective therapies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Y-mAbs Therapeutics' pipeline includes several clinical-stage products that target various types of cancer, including neuroblastoma, pediatric brain tumors, and lymphoma. The company's lead product candidate, Danyelza (naxitamab-gqgk), is a monoclonal antibody that has been approved by the FDA for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
Y-mAbs Therapeutics uses a proprietary antibody platform technology called omburtamab, which enables the development of highly targeted and specific antibody-based therapies. The company also has collaborations with leading academic institutions and pharmaceutical companies to advance its research and development efforts.
Y-mAbs Therapeutics is committed to improving the lives of patients with cancer by developing innovative and effective therapies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!